Unroofed Coronary Sinus Associated with Persistent Left Superior Vena Cava : Detection by Agitated Saline Contrast Echocardiography

Kyu-Jin OH; Wook-Jin CHUNG; Mi-Seung SHIN; Mi-Young HAN; Woong-Chol KANG; Kyung-Leem CHOI; Pil-Seon YANG; Sung-Yong KIM; Tae-Hoon AHN; Eak-Kyun SHIN.
Journal of the Korean Society of Echocardiography ; : 49-53, 2004.
Artículo en Ko | WPRIM | ID: wpr-152626

Documentos relacionados

  1. Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
  2. Binding Interactions of Ergotamine and Dihydroergotamine to 5-Hydroxytryptamine Receptor 1B (5-HT<sub>1b</sub>) Using Molecular Dynamics Simulations and Dynamic Network Analysis.
  3. Drug Repurposing to Inhibit Histamine <i>N</i>-Methyl Transferase.
  4. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
  5. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
  6. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>®</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
  7. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
  8. Dihydroergotamine extravasation: prolonged arterial vasospasm requiring medical and surgical treatment.
  9. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
  10. Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review.